Transfer of Blastocysts in cryopreseved cycles
Not Applicable
Completed
- Conditions
- Infertility.Complication associated with artificial fertilization, unspecifiedN98.9
- Registration Number
- IRCT201107306420N7
- Lead Sponsor
- Yazd research and clinical center for infertility
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 150
Inclusion Criteria
women underwent previously in vitro fertilization (IVF) or intra-cytoplasmicsperm injection (ICSI) with embryo cryopreservation
Exclusion Criteria
History of diabetes mellitus
Thyroid disease
Severe endometriosis
Oocyte donation cycles
Women with age>35 years
Body mass index (BMI)>30 kg/m2
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Chemical pregnancy. Timepoint: 14 days after embryo transfer. Method of measurement: Blood laboartory kit.;Clinical pregnancy. Timepoint: 5 weeks after positive beta-hCG. Method of measurement: Observation of fetal heart activity by transvaginal ultrasonography.;Ongoing pregnancy. Timepoint: 12 weeks after embryo transfer. Method of measurement: Ultrasonography.
- Secondary Outcome Measures
Name Time Method Miscarriage rate. Timepoint: Lost of pregnancy before 20 gestational week. Method of measurement: Absence of fetal heart activity in ultra sound sonography.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms underlying blastocyst transfer in cryopreserved cycles for infertility treatment?
How does blastocyst transfer from frozen-thawed cleavage stage embryos compare to fresh embryo transfer in terms of pregnancy outcomes and implantation rates?
Are there specific biomarkers that predict successful pregnancy outcomes following cryopreserved blastocyst transfer in patients with N98.9 complications?
What are the potential adverse events associated with cryopreserved blastocyst transfer and how can they be managed in clinical practice?
What combination approaches or alternative therapies are being explored alongside blastocyst transfer for improving fertility outcomes in patients with unspecified artificial fertilization complications?